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Abstract: The incidence of post transplant viral infections has increased with the use of more potent immunosuppressive 
regimens. Consequently, BK virus nephropathy (BKVN) has arisen as a significant cause of graft dysfunction and loss. 
Reduction of immunosuppression is the first line management of post-transplant viral infections. Other therapies such as 
intravenous immunoglobulin (IVIg), cidofovir, leflunomide and fluoroquinolones have been tried with varying degrees of 
success. 
We report our experience with IVIg in three pediatric renal transplant recipients who presented with allograft dysfunction. 
First, we describe two cases of biopsy proven BKVN, one diagnosed with undetectable viral titers in plasma, 
demonstrating that BKVN can occur even at low viral loads. We also present a pediatric renal transplant recipient with 
persistent BK viremia and allograft dysfunction who responded to therapy with recovery of renal function and clearance 
of viremia. Therefore we conclude that IVIg is efficacious in the treatment of persistent BK viremia and BKVN. The 
appropriate dose, frequency and duration of therapy require further study. 
Keywords: Allograft dysfunction, BK viremia, BK virus nephropathy (BKVN), immunosuppression reduction, intravenous 
immunoglobulin (IVIg), pediatric transplantation. 
INTRODUCTION 
 BK virus nephropathy (BKVN) has become of significant 
concern as a cause of graft dysfunction and loss in the renal 
transplant population. Dormant BK virus is reactivated in the 
setting of increased immunosuppression, causing tubulo-
interstitial nephritis in up to 8% of patients [1]. Presently no 
standard therapy for BK viremia and nephropathy has been 
established. 
 Reduction in immunosuppression is accepted as the first 
line therapy in the management of BKVN [2]. The use of 
leflunomide, cidofovir, IVIg and fluoquinolones as adjunct 
therapy in addition to immunosuppression reduction in the 
management of BK virus nephropathy has been evaluated in 
several small clinical studies [3-6]. There have however been 
no prospective randomized studies to compare the various 
agents and provide much needed information on long-term 
benefits. 
 Human intravenous immunoglobulin has immunomodu-
latory properties and has been used successfully for 
transplant related indications including treatment of antibody 
mediated rejection; desensitization of highly sensitized 
transplant recipients and in treatment of post-transplant 
infectious complications like parvovirus B19, cytomegalo-
virus and BKVN [7]. 
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 One of the authors, Anyaegbu et al., has previously 
reported her experience using IVIg for treatment of 
persistent BK viremia and BK nephropathy [4]. There have 
been conflicting reports on the efficacy of IVIg in the 
treatment of BKVN. Majority of the reports have described 
successful use in the management of BKVN. However there 
have been reports of an increase in BK viral load following 
IVIg therapy [8, 9]. 
 We conducted a retrospective review at the Washington 
University in St Louis of pediatric renal transplant recipients 
who received IVIg therapy for management of BKVN and 
report our successful treatment of BK viremia and 
nephropathy with immunosuppression reduction and 
administration of IVIg. Patients were screened for BK virus 
when they presented with elevations in serum creatinine. 
This was before the implementation of our prospective 
screening protocol for BK viriuria and viremia. Our first line 
strategy for management of BK viremia was 
immunosuppression reduction, which was sufficient therapy 
in the majority of patients. Three patients were diagnosed 
with BKVN and received IVIg following an inadequate 
response to only immunosuppression reduction. The 
therapeutic benefit of IVIg after an insufficient response to 
immunosuppression reduction was demonstrated in these 
patients. Our report shows that administration of IVIg is an 
effective option for the management of BKVN. 
CASE 1 
 A 15-year-old Caucasian male with end stage renal 
disease secondary to complications of William’s syndrome 
received a renal transplant from a cadaveric donor. At the 
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time of transplantation both the donor and recipient were 
positive for cytomegalovirus. Induction agents included 5 
doses of rabbit Thymoglobulin and pulse steroids that were 
rapidly tapered. There was excellent graft function with rapid 
decline in serum creatinine. He was maintained on a steroid 
free regimen consisting of tacrolimus and mycophenolate 
mofetil. Ureteral stents were removed 1 month after 
transplant and graft function remained stable at a baseline of 
0.7- 0.9 mg/dl. 
 Two years post-transplant, his serum creatinine increased 
to 1.5 mg/dl. BK viremia was confirmed by quantitative 
detection of BK virus in plasma. BK viral titers in urine and 
plasma at diagnosis were greater than 1 X 106 copies and 
1.39 X 106 respectively. An allograft biopsy showed diffuse 
tubulointerstitial inflammation and a positive stain for 
Simian virus 40 (SV-40) large T-antigen. C4d staining was 
negative. His mycophenolate mofetil was discontinued and 
his tacrolimus dose was reduced to 1mg twice a day 
targeting tacrolimus troughs of 3- 4 ng/ml. There was an 
inadequate response to reduction in immunosuppression, 
which prompted administration of IVIg. He received 6 doses 
of IVIg (0.5 g/kg) monthly with clearance of viremia and 
improvement in allograft function. 
CASE 2 
 A second patient was diagnosed with BKVN by biopsy. 
He was found to have nephropathy in the setting of only BK 
viruria and negative BK in plasma 77 days post transplant. 
Urine viral titers were 3.23 X 106 with undetectable BK titers 
in plasma. He received a heart transplant as an infant and 
subsequently developed end stage renal disease from 
cyclosporine nephrotoxicity. He received a living related 
kidney from his mother. Induction	   immunosuppression	  consisted	   of	   rabbit Thymoglobulin 1.5	  mg/kg/dose	   given	  daily	   for	   a	   total	   of	   5	   doses	   and	   pulse	   intravenous	  methylprednisolone	   for	   4	   days.	   This	   was	   followed	   by	  maintenance	   immunosuppression	   with	   mycophenolate	  mofetil	  and	  tacrolimus.	  
 During a routine post-transplant follow-up visit, his 
serum creatinine was found to have increased to 0.8mg/dl 
from a baseline of 0.4mg/dl, prompting a biopsy that showed 
a positive SV-40 stain. Immunosuppression was reduced by 
withdrawal of mycophenolate mofetil and reduction in the 
dose of tacrolimus to target trough levels of 4-5 ng/ml. 
 Viral clearance and improvement in graft function was 
achieved with reduction in immunosuppression and monthly 
IVIg (0.5 g/kg) therapy for 6 months. His graft function 
however did not return to his previous baseline. 
CASE 3 
 A 16-year-old Hispanic male who was an illegal 
immigrant received a cadaveric kidney transplant due to end 
stage renal disease secondary to nephronopthisis. Graft 
function was excellent following induction with rabbit 
Thymoglobulin and pulse steroid therapy. He was 
maintained on a steroid free regimen consisting of tacrolimus 
and mycophenolate mofetil. He developed acute rejection 
due to missed doses of immunosuppressive medications that 
resulted from insufficient funds to purchase medications. He 
was treated with Thymoglobulin and pulse steroid therapy 
with recovery of function to his previous baseline of 0.9 
mg/dl. 
 A few months later, he was found to have an elevation in 
his serum creatinine. His serum creatinine peaked at 2.2 
mg/dl. BK viremia was detected and his immunosuppression 
was reduced. Initially the dose of mycophenolate mofetil 
was reduced by 50% and with persistent viremia was 
discontinued. The next step was a staged reduction in 
tacrolimus dosing to target troughs of 4-5 ng/ml. With 
persistent viremia, he received IVIg. Viral clearance was 
seen after 5 monthly doses of 0.5g/kg with stabilization of 
graft function and a decrease in serum creatinine to 1 mg/dl. 
DISCUSSION 
 Pediatric renal transplant recipients are at high risk for 
BK virus infection post transplant because they are more 
likely to be naïve to the BK virus. Other risk factors include 
HLA mismatch, the intensity of immunosuppression with an 
increased incidence following treatment of rejection with 
intensified immunosuppression using lymphocyte-depleting 
therapy [10]. 
 Prospective screening protocols have led to earlier 
detection of BK viremia, which has helped minimize the 
effect of BKVN on graft survival. Nonetheless, with 
detection of BK viruria and viremia, there is insufficient 
evidence to support additional therapy if there is an 
inadequate response to reduction in immunosuppressive 
therapy or in the face of established nephropathy. 
 Reduction in immunosuppression is accepted as the first-
line management of BK viremia and nephropathy [2]. It has 
been used as the sole therapy for BK viremia and 
nephropathy [11]. The strategy for targeted reduction in 
immunosuppression varies among transplant centers. The 
most common approach involves decreasing and then 
discontinuation of the anti-proliferative agent. The 
calcineurin inhibitor is then decreased if viremia persists. In 
a cohort study, Schaub et al. outlined their reduction 
protocol, which initially involves reduction in calcineurin 
therapy by targeting lower trough levels. This was done by 
setting a lower tacrolimus trough than would be expected for 
the post-transplant period i.e. targeting a trough of 6-8 ng/ml 
instead of a trough of 8-10 ng/ml. If viremia persisted, the 
calcineurin inhibitor was further reduced (eg the tacrolimus 
trough levels were decreased from 6-8 to 4-6 ng/ml). The 
final stage in the protocol was a sequential reduction in 
mycophenolate moefetil dosing in increments of 50%. Using 
this staged reduction protocol, viral clearance and 
stabilization of graft function was seen with 
immunosuppression reduction alone [11]. Reduction in 
immunosuppression is however associated with an increased 
incidence of acute rejection which has been reported in up to 
25% of cases [12]. 
 Reports have described the use of agents like cidofovir, 
leflunomide, fluoroquinolones and IVIg with varied success 
[3-5, 13, 14]. Cidofovir has anti-polyoma activities, which 
has been demonstrated in in vitro experiments. It is however 
extremely nephrotoxic which limits its use for management 
of BKVN. It has also been associated with a recurrence of 
BK viremia and persistent BKVN after an initial response 
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[6]. Leflunomide has anti-viral properties against BK virus 
and is an attractive option for treatment of BKVN since it 
has minimal nephrotoxicity. It has been used successfully in 
adult and pediatric transplant recipients in combination with 
immunosuppression reduction [3, 13]. Fluoroquinolones 
inhibits polyoma virus replication in vitro and has been 
shown to decrease BK viral load. It has been used as a 
prophylactic agent. Garbardi et al. demonstrated a 
significantly lower incidence of BK viremia at 1 year in a 
cohort of 160 patients who received fluoroquinolone therapy 
for prophylaxis for at least 1 month post-transplant [5]. 
 Case reports have emerged that have documented an 
increase in BK viral load following administration of IVIg. 
Boonyapredee M et al, reported their experience with a 57-
year old female renal transplant recipient who underwent a 
biopsy for allograft dysfunction in the setting of BK viremia 
8 weeks post-transplant. The histological findings were 
consistent with Banff 1b acute cellular rejection and a 
negative stain for SV-40 and negative C4d staining of 
peritubular capillaries. The patient was given 2 g/kg of IVIg 
with no adjustments to her baseline immunosuppression 
since there was inadequate evidence to make a diagnosis of 
BKVN. Her BK viral load increased exponentially after 
administration of IVIg with a further increase in her serum 
creatinine. A repeat biopsy revealed a positive SV-40 stain 
within the epithelial cells of the tubules and moderate 
tubulitis. Her immunosuppression was promptly decreased 
and she received leflunomide for treatment of BKVN and a 
steroid pulse for treatment of concurrent acute cellular 
rejection. Her BK viral load decreased subsequently and 
there was improvement in her graft function reported [8]. 
 This finding is similar to a report by Maggiore et al. who 
describes the case of a 49-year old woman who underwent a 
renal biopsy when she presented with an elevation in her 
serum creatinine up to 2.4mg/dl from a baseline of 1.6 - 1.8 
mg/dl 14 months post-transplant. She was found to have 
BKVN and immunosuppression was reduced and she 
received 2g/kg of IVIg over 5 days. Her BK viral load was 
closely monitored and observed to increase in the first week 
following IVIg therapy from 7720 copies/ml to a peak of 
144,440-copies/ ml after IVIg administration before a 
progressive decline was seen over a 12-week period. Her 
graft function showed gradual improvement with a decrease 
in her serum creatinine to a new baseline of 2 mg/dl in the 
29-month follow-up period [9]. 
 IVIg has anti-inflammatory and BK neutralizing 
properties demonstrated in in vitro experiments [15]. It has 
been used for treatment of BKVN following an inadequate 
response to reduction in immunosuppression and has been 
reported to lead to a stabilization of allograft function, 
clearance of viremia and histological resolution of BKVN [4, 
14]. 
 Reports exist on adult and pediatric transplant recipients 
with BK viremia and nephropathy where IVIg was used with 
improvement in renal function and significant graft survival 
demonstrated. There was similarity in the dosing strategies 
for IVIg in the reports of the largest adult and pediatric 
cohorts [4, 14]. There reports provided some insight into the 
utility of IVIg combined with immunosuppression reduction  
 
without the confounding effects of other therapeutic agents. 
In the report by Sharma et al, stabilization of renal function 
and histological resolution of BKVN was seen with IVIg 
after recurrent BK viremia developed with discontinuation of 
cidofovir therapy [6]. 
 We utilized low dose IVIg treatments (0.5 g/kg) given 
monthly over a 5 to 6 month period, which was similar to the 
protocol described by Sharma et al. [6]. The most common 
side effect seen was post infusion headache, which was 
easily managed with acetaminophen. No case of acute 
kidney injury was seen in our cohort as a result of IVIg 
therapy. Our choice of low dose therapy distributed over a 
period of time was based on the regimen used to treat other 
post transplant viral infections. It was effective and led to 
better inhibition of viral replication and better overall viral 
eradication since viral clearance is usually slow in the face of 
immunosuppression. Using low dose therapy also helped to 
minimize the infusion related complications frequently seen 
with high dose therapy. 
 Our findings highlight the effectiveness of IVIg as 
second line therapy following a suboptimal response to 
immunosuppression reduction and offer an alternative 
therapy to the current management strategies. The optimal 
dosing, frequency and duration of therapy needs to be 
determined. Also, the indication for treatment, cost 
effectiveness, availability and side effect profile require 
further study. 
 The fact that the histological features of BKVN on light 
microscopy are often difficult to distinguish from acute 
cellular rejection and BKVN sometimes coexist with 
rejection makes IVIg an attractive alternative strategy. Its 
anti-BK attributes together with the anti-rejection effects 
make it a unique therapeutic option in protecting against 
rejection, which can occur following reduction of 
immunosuppression. It is also the ideal treatment when the 
diagnosis is unclear or while awaiting results of the SV-40 
staining for the BK virus. 
 Despite being expensive and in limited supply, IVIg is an 
appealing therapeutic option for the rising threat of BK 
viremia and BKVN in the setting of less well-defined 
options. Further study is needed to compare its efficacy to 
the other management options and longer follow-up is 
required to evaluate long-term benefits and graft survival. 
ABBREVIATIONS 
BKVN = BK virus nephropathy 
IVIg = Intravenous immunoglobulin 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no conflict 
of interest. 
ACKNOWLEDGEMENTS 
 This project was supported by the Washington University 
in St Louis Institute of Clinical and Translational Sciences 
(ICTS) UL1 grant. 
132    The Open Urology & Nephrology Journal, 2014, Volume 7 Anyaegbu and Hmiel 
REFERENCES 
[1] Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study 
of polyomavirus type BK replication and nephropathy in renal-
transplant recipients. N Engl J Med 2002; 347(7): 488-96. 
[2] Hirsch HH, Randhawa P. BK virus in solid organ transplant 
recipients. Am J Transplant 2009; 9 Suppl 4: S136-46. 
[3] Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. 
Leflunomide therapy for BK virus allograft nephropathy in 
pediatric and young adult kidney transplant recipients. Pediatric 
transplant 2010; 14(1): 145-50. 
[4] Anyaegbu EI, Almond PS, Milligan T, Allen WR, Gharaybeh S, 
Al-Akash SI. Intravenous immunoglobulin therapy in the treatment 
of BK viremia and nephropathy in pediatric renal transplant 
recipients. Pediatric transplant 2012; 16(1): E19-24. 
[5] Gabardi S, Waikar SS, Martin S, et al. Evaluation of 
fluoroquinolones for the prevention of BK viremia after renal 
transplantation. Clin J Am Soc Nephrol 2010; 5(7): 1298-304. 
[6] Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J. 
Intravenous immunoglobulin as rescue therapy for BK virus 
nephropathy. Pediatric transplant 2009; 13(1): 123-9. 
[7] Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of 
intravenous immunoglobulin use in solid organ transplant 
recipients. Am J Trnsplant 2011; 11(2): 196-202. 
[8] Boonyapredee M, Knight K, Little D. Increased BK viremia and 
progression to BK-virus nephropathy following high-dose 
intravenous immunoglobulin for acute cellular rejection. Mil Med 
2014; 179(6): e699-702. 
[9] Maggiore U, Medici MC, Vaglio A, Buzio C. Increased viral load 
after intravenous immunoglobulin therapy for BK virus-associated 
nephropathy. Transpl Infect Dis 2010; 12(5): 470-2. 
[10] Prince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, 
Mihatsch MJ. Risk factors for polyoma virus nephropathy. Nephrol 
Dial Transplant 2009; 24(3): 1024-33. 
[11] Schaub S, Hirsch HH, Dickenmann M, et al. Reducing 
immunosuppression preserves allograft function in presumptive 
and definitive polyomavirus-associated nephropathy. Am 
J Transplant 2010; 10(12): 2615-23. 
[12] Bohl DL, Brennan DC. BK virus nephropathy and kidney 
transplantation. Clin J Am Soc Nephrol 2007; 2 (Suppl 1): S36-46. 
[13] Josephson MA, Gillen D, Javaid B, et al. Treatment of renal 
allograft polyoma BK virus infection with leflunomide. 
Transplantation 2006; 81(5): 704-10. 
[14] Sener A, House AA, Jevnikar AM, et al. Intravenous 
immunoglobulin as a treatment for BK virus associated 
nephropathy: one-year follow-up of renal allograft recipients. 
Transplantation 2006; 81(1): 117-20. 
[15] Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. 
Polyomavirus BK neutralizing activity in human immunoglobulin 
preparations. Transplantation 2010; 89(12): 1462-5. 
 
 
Received: September 25, 2014 Revised: October 1, 2014 Accepted: October 2, 2014 
 
© Anyaegbu and Hmiel.; Licensee Bentham Open. 
 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 
